TerminatedPhase 2

Randomized Study of Letrozole and Trilostane for Medical Abortion

Stopped: No access to study drug Trilostan. Company closed down

Sweden36 participantsStarted 2012-05

Plain-language summary

In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy women aged 18-45 without any contraindication for treatment of any of the drugs involved in teh study Exclusion Criteria: * Any ongoing medication or medical condition smoking \>20 cigarettes per day BMI \>30

What they're measuring

efficacy

Timeframe: 4 weeks

Trial details

NCT IDNCT01615211

SponsorKristina Gemzell Danielsson

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-10

View on ClinicalTrials.gov More Medical Abortion, Complete or Unspecified, Without Complication trials